Syndax Pharmaceuticals (SNDX) Debt to Equity (2020 - 2024)
Historic Debt to Equity for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q4 2024 value amounting to $1.19.
- Syndax Pharmaceuticals' Debt to Equity changed N/A to $1.19 in Q4 2024 from the same period last year, while for Dec 2024 it was $1.19, marking a year-over-year change of. This contributed to the annual value of $1.19 for FY2024, which is N/A changed from last year.
- Per Syndax Pharmaceuticals' latest filing, its Debt to Equity stood at $1.19 for Q4 2024.
- Syndax Pharmaceuticals' Debt to Equity's 5-year high stood at $1.19 during Q4 2024, with a 5-year trough of $0.05 in Q4 2021.
- Its 4-year average for Debt to Equity is $0.22, with a median of $0.09 in 2021.
- The largest annual percentage gain for Syndax Pharmaceuticals' Debt to Equity in the last 5 years was 2960.65% (2021), contrasted with its biggest fall of 7602.86% (2021).
- Quarter analysis of 4 years shows Syndax Pharmaceuticals' Debt to Equity stood at $0.08 in 2020, then plummeted by 38.36% to $0.05 in 2021, then rose by 13.52% to $0.06 in 2022, then surged by 2036.64% to $1.19 in 2024.
- Its last three reported values are $1.19 in Q4 2024, $0.06 for Q2 2022, and $0.05 during Q1 2022.